+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants



Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants



Vaccine 21(17-18): 2097-2106



An effective vaccination strategy against human immunodeficiency virus type 1 (HIV-1) should include the induction of potent cellular immune responses against conserved HIV-1 antigens. We have generated five replication competent recombinant influenza viruses (rFlu/SIV Gag nos. 1-5) expressing different portions of Gag of simian immunodeficiency virus (SIV). Single intranasal immunizations in mice with each rFlu/SIV Gag viruses resulted in different degrees of protection against a challenge with recombinant vaccinia virus expressing SIV Gag. Immunized BALB/c mice had detectable CD8+ T cell responses specific for Gag peptide 185-199 when mice were vaccinated with rFlu/SIV Gag no. 3 virus, and for Gag peptides 281-295 and 285-299 when vaccinated with rFlu/SIV Gag no. 4 virus. Cellular immune responses against SIV Gag were further enhanced by a booster with a recombinant vaccinia virus expressing SIV Gag in both the spleen and local lymph node tissues, resulting in the induction of robust Gag-specific CD8+ T cell responses at both systemic and mucosal levels. We suggest that a prime-boost immunization regimen using recombinant influenza and vaccinia viruses expressing HIV Gag might represent an effective means to induce potent HIV-specific, protective CD8+ T cell responses.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010589120

Download citation: RISBibTeXText

PMID: 12706700

DOI: 10.1016/s0264-410x(02)00781-8


Related references

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17(7-8): 887-892, 1999

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. Journal of Virology 77(12): 7048-7057, 2003

Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. Microbial Pathogenesis 1(5): 443-452, 1986

Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. Journal of General Virology 70: 1523-1531, 1989

Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara recombinant A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve vector. Vaccine 20(5-6): 961-971, 12 December, 2001

Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine 20(5-6): 961-971, 2001

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Research 63(22): 7942-7949, 2003

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. European Journal of Immunology 16(12): 1479-1487, 1986

Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune system. Chanock, R M , Et Al (Ed ) Vaccines, 87 Modern Approaches to New Vaccines: Prevention Of Aids And Other Viral, Bacterial, And Parasitic Diseases; Conference, Cold Spring Harbor, New York, Usa, 1986 Xxiii+461p Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, Usa Illus Paper 72-76, 1987

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges. Mbio 6(4): E01005, 2016

Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17(9-10): 1074-1083, 1999

Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV). Virus Genes 35(3): 585-595, 2007

Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms). Scandinavian Journal of Immunology 27(6): 645-652, 1988

DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. Journal of Virology 77(1): 382-390, 2002

Dna Immunization with Hepatitis C Virus (Hcv) Polycistronic Genes or Immunization by Hcv Dna Priming-Recombinant Canarypox Virus Boosting Induces Immune Responses and Protection from Recombinant Hcv-Vaccinia Virus Infection in Hla-A2.1-Transgenic Mice. Journal of Virology 77(1): 382-390, 2003